Inhibition of RPL26 and RPL29 in these cells is associated with reduced proliferation, increased apoptosis and blockage of cell cycle, which shed light on the importance of targeting these RPs as a potential therapy of pancreatic cancer. Here, RPL29 is linked to pancreatic neoplasm.